The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating
hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell …

Chimeric antigen receptor (CAR) T-cell therapies have shown impressive results in patients
with hematological malignancies; however, little success has been achieved in the treatment …

Macrophages and neutrophils are the main components of the innate immune system and
play important roles in promoting angiogenesis, extracellular matrix remodeling, cancer cell …

Chimeric antigen receptor (CAR)-T cell therapy has been shown to be an effective treatment
for hematological tumors, but the treatment of solid tumors still lacks effectiveness. In the …

Background Macrophages have recently become attractive therapeutics in cancer
immunotherapy. The potential of macrophages to infiltrate and influence solid malignancies …

Today, adoptive cell therapy has many successes in cancer therapy, and this subject is
brilliant in using chimeric antigen receptor T cells. The CAR T cell therapy, with its FDA …

Chimeric antigen receptor (CAR) T cell treatment has provided notable results in
hematological tumors. Unfortunately, this evidence has not been translated into improved …

Chimeric antigen receptor (CAR)-expressing macrophages (CAR-M) have a great potential
to improve cancer therapy, as shown from several recent preclinical studies. However …

The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic.
However, there are still major challenges for its wider applications in a variety of cancer …

Expressing chimeric antigen receptors (CARs) in macrophages has led to promising results
in preclinical and clinical work. Now, induced pluripotent stem cells have been combined …